journal article
Open Access
Mar 26, 2026
Value, development challenges, and strategies for gaining internal endorsement of digitally connected subcutaneous drug delivery devices: a survey of pharmaceutical stakeholders
Abstract
Introduction
Connected drug delivery devices such as combination products that integrate traditional drug delivery systems with digital connectivity features represent an opportunity to improve treatment outcomes and disease management. This online survey study was conducted to explore the evolving landscape of digitally connected subcutaneous (SC) drug delivery devices, including the perspectives of pharmaceutical stakeholders regarding the promise of these technologies, particularly in relation to the expansion of traditional mobile companion applications and their integration in drug delivery systems.
Methods
A total of 80 employees of pharmaceutical, biotechnology, or digital health companies with primary roles in medical affairs, commercial, combination product development, or digital health who had experience working on SC drug-device combination products completed the survey. Survey questions explored the value propositions of connected SC drug delivery devices for patients, providers, and payers; barriers to the adoption of these technologies; and strategies for gaining internal support for connected healthcare initiatives.
Results
Responses demonstrated that industry professionals recognize the potential value of connected SC drug delivery devices and associated companion mobile applications and are investing in bringing them to market. Nearly all respondents (97.5%) reported that connectivity is at least moderately important to achieving important objectives, including acquiring real-world data, improving medication adherence, and enhancing ease-of-use for patients. Equal potential value was noted for using connectivity in clinical trials or commercial settings, with neither considered more beneficial than the other. Indications in oncology and endocrinology were considered to be the most likely to benefit from connected SC drug delivery devices. Key barriers to the adoption of connected SC drug delivery devices were development cost, data security, and patient and payer acceptance, while generating evidence of internal and external value was noted as a significant barrier to gaining company endorsement.
Discussion
These results should guide strategies for the effective integration of connected healthcare solutions within the pharmaceutical sector.
Connected drug delivery devices such as combination products that integrate traditional drug delivery systems with digital connectivity features represent an opportunity to improve treatment outcomes and disease management. This online survey study was conducted to explore the evolving landscape of digitally connected subcutaneous (SC) drug delivery devices, including the perspectives of pharmaceutical stakeholders regarding the promise of these technologies, particularly in relation to the expansion of traditional mobile companion applications and their integration in drug delivery systems.
Methods
A total of 80 employees of pharmaceutical, biotechnology, or digital health companies with primary roles in medical affairs, commercial, combination product development, or digital health who had experience working on SC drug-device combination products completed the survey. Survey questions explored the value propositions of connected SC drug delivery devices for patients, providers, and payers; barriers to the adoption of these technologies; and strategies for gaining internal support for connected healthcare initiatives.
Results
Responses demonstrated that industry professionals recognize the potential value of connected SC drug delivery devices and associated companion mobile applications and are investing in bringing them to market. Nearly all respondents (97.5%) reported that connectivity is at least moderately important to achieving important objectives, including acquiring real-world data, improving medication adherence, and enhancing ease-of-use for patients. Equal potential value was noted for using connectivity in clinical trials or commercial settings, with neither considered more beneficial than the other. Indications in oncology and endocrinology were considered to be the most likely to benefit from connected SC drug delivery devices. Key barriers to the adoption of connected SC drug delivery devices were development cost, data security, and patient and payer acceptance, while generating evidence of internal and external value was noted as a significant barrier to gaining company endorsement.
Discussion
These results should guide strategies for the effective integration of connected healthcare solutions within the pharmaceutical sector.
Topics
No keywords indexed for this article. Browse by subject →
References
62
[1]
(2024)
[2]
Buttorff (2017) 10.7249/tl221
[3]
(2025)
[4]
Brown "Medication adherence: truth and consequences" Am J Med Sci (2016) 10.1016/j.amjms.2016.01.010
[5]
Ghimire "Nonadherence to medication therapy in haemodialysis patients: a systematic review" PLoS One (2015) 10.1371/journal.pone.0144119
[6]
Kripalani "Medication nonadherence before hospitalization for acute cardiac events" J Health Commun (2015) 10.1080/10810730.2015.1080331
[7]
Jackson "Factors associated with non-adherence to oral medication for inflammatory bowel disease: a systematic review" Am J Gastroenterol (2010) 10.1038/ajg.2009.685
[8]
Bernal "Medication-taking behavior in a cohort of patients with inflammatory bowel disease" Dig Dis Sci (2006) 10.1007/s10620-006-9444-2
[9]
Belcon "A critical review of compliance studies in rheumatoid arthritis" Arthritis Rheum (1984) 10.1002/art.1780271104
[10]
Kołtuniuk "The quality of life and medication adherence in patients with multiple sclerosis-cross-sectional study" Int J Environ Res Public Health (2022) 10.3390/ijerph192114549
[11]
Mendoza-Pinto "Medication adherence is influenced by resilience in patients with systemic lupus erythematosus" Lupus (2021) 10.1177/09612033211004722
[12]
Krass "Adherence to diabetes medication: a systematic review" Diabet Med (2015) 10.1111/dme.12651
[13]
Cutler "Economic impact of medication non-adherence by disease groups: a systematic review" BMJ Open (2018) 10.1136/bmjopen-2017-016982
[14]
van Mierlo "Targeting medication non-adherence behavior in selected autoimmune diseases: a systematic approach to digital health program development" PLoS One (2015) 10.1371/journal.pone.0129364
[15]
Alsbrooks "Prevalence, causes, impacts, and management of needle phobia: an international survey of a general adult population" PLoS One (2022) 10.1371/journal.pone.0276814
[16]
Krueger "Medication adherence and persistence: a comprehensive review" Adv Ther (2005) 10.1007/bf02850081
[17]
Kini "Interventions to improve medication adherence: a review" JAMA (2018) 10.1001/jama.2018.19271
[18]
Marsch "The application of digital health to the assessment and treatment of substance use disorders: the past, current, and future role of the national drug abuse treatment clinical trials network" J Subst Abuse Treat (2020) 10.1016/j.jsat.2020.02.005
[19]
Rafiei "Digital health integration assessment and maturity of the United States biopharmaceutical industry: forces driving the next generation of connected autoinjectable devices" JMIR Mhealth Uhealth (2021) 10.2196/25406
[20]
Bittner "Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting" Med Devices (Auckl) (2019) 10.2147/mder.s198943
[21]
Marra "Quantifying the use of connected digital products in clinical research" NPJ Digit Med (2020) 10.1038/s41746-020-0259-x
[22]
Bayas "Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study" Expert Opin Drug Deliv (2015) 10.1517/17425247.2015.1057567
[23]
Kleiter "Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT(R) autoinjector: a prospective observational cohort study" BMC Neurol (2017) 10.1186/s12883-017-0953-8
[24]
Edo-Solsona "Impact of adherence on subcutaneous interferon Beta-1a effectiveness administered by rebismart® in patients with multiple sclerosis" Value Health (2016) 10.1016/j.jval.2016.09.512
[25]
de Arriba "Use of connected injection device has a positive effect on catch-up growth in patients with growth disorders treated with growth hormone therapy" Front Endocrinol (Lausanne) (2024) 10.3389/fendo.2024.1450573
[26]
Desai "Evaluating unmet needs in large-volume subcutaneous drug delivery: U.S. payer perspectives on a novel, large-volume on-body delivery system" Curr Med Res Opin (2024) 10.1080/03007995.2024.2351165
[27]
Fernández "Long-term adherence to IFN Beta-1a treatment when using RebiSmart® device in patients with relapsing-remitting multiple sclerosis" PLoS One (2016) 10.1371/journal.pone.0160313
[28]
Kühler "Development and regulation of connected combined products: reflections from the medtech & pharma platform association" Clin Ther (2022) 10.1016/j.clinthera.2022.03.009
[29]
Hobbins (2024)
[30]
(2020)
[31]
(2024)
[32]
(2016)
[33]
Mulcahy "Show me the money: commercialization, business models, case-studies" (2024)
[34]
Martin-Ruiz "Systematic review of the effect of adherence to statin treatment on critical cardiovascular events and mortality in primary prevention" J Cardiovasc Pharmacol Ther (2018) 10.1177/1074248417745357
[35]
Marcatto "Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range" J Thromb Thrombolysis (2021) 10.1007/s11239-020-02280-8
[36]
Yang "High rates of secondary non-adherence causes decreased efficacy of 0.1% topical tacrolimus in adult eczema patients: results from a multicenter clinical trial" J Dermatolog Treat (2018) 10.1080/09546634.2017.1350256
[37]
Lerman "Adherence to treatment: the key for avoiding long-term complications of diabetes" Arch Med Res (2005) 10.1016/j.arcmed.2004.12.001
[38]
Rockstroh "Adherence to enfuvirtide and its impact on treatment efficacy" AIDS Res Hum Retroviruses (2008) 10.1089/aid.2006.0231
[39]
Garnett "Antiepileptic drug treatment: outcomes and adherence" Pharmacotherapy (2000) 10.1592/phco.20.12.191s.35250
[40]
Kaslow "Adherence to guidelines at the patient- and hospital-levels is associated with improved overall survival in patients with gastric cancer" J Surg Oncol (2022) 10.1002/jso.26895
[41]
Wheaton "Patient adherence and treatment outcome with exposure and response prevention for OCD: which components of adherence matter and who becomes well?" Behav Res Ther (2016) 10.1016/j.brat.2016.07.010
[42]
Gau "National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan" J Clin Psychiatry (2008) 10.4088/jcp.v69n0118
[43]
Novick "Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia" Psychiatry Res (2010) 10.1016/j.psychres.2009.05.004
[44]
Sumino "Medication adherence in asthma patients" Curr Opin Pulm Med (2013) 10.1097/mcp.0b013e32835b117a
[45]
Mäkelä "Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD" Respir Med (2013) 10.1016/j.rmed.2013.04.005
[46]
Fransen "Influence of guideline adherence on outcome in a randomised controlled trial on the efficacy of methotrexate with folate supplementation in rheumatoid arthritis" Ann Rheum Dis (2004) 10.1136/ard.2003.018861
[47]
Adolfsson "Increased time in range and fewer missed bolus injections after Introduction of a smart connected insulin pen" Diabetes Technol Ther (2020) 10.1089/dia.2019.0411
[48]
Pauls "Substance and bias in social desirability responding" Pers Individ Dif (2003) 10.1016/s0191-8869(02)00187-3
[49]
Latkin "Social desirability response bias and other factors that may influence self-reports of substance use and HIV risk behaviors: a qualitative study of drug users in Vietnam" AIDS Educ Prev (2016) 10.1521/aeap.2016.28.5.417
[50]
Catalani "Mhealth for HIV treatment & prevention: a systematic review of the literature" Open AIDS J (2013) 10.2174/1874613620130812003
Showing 50 of 62 references
Metrics
0
Citations
62
References
Details
- Published
- Mar 26, 2026
- Vol/Issue
- 8
- License
- View
Authors
Cite This Article
Aaron Swick, S. Prasad Peri, Tanisha Hill, et al. (2026). Value, development challenges, and strategies for gaining internal endorsement of digitally connected subcutaneous drug delivery devices: a survey of pharmaceutical stakeholders. Frontiers in Digital Health, 8. https://doi.org/10.3389/fdgth.2026.1684685
Related
You May Also Like
Current challenges and potential solutions to the use of digital health technologies in evidence generation: a narrative review
Hassan Mumtaz, Muhammad Hamza Riaz · 2023
230 citations
Digital Mental Health for Young People: A Scoping Review of Ethical Promises and Challenges
Blanche Wies, Constantin Landers · 2021
205 citations
Artificial intelligence in positive mental health: a narrative review
Anoushka Thakkar, Ankita Gupta · 2024
174 citations
Artificial Intelligence Solutions to Increase Medication Adherence in Patients With Non-communicable Diseases
Aditi Babel, Richi Taneja · 2021
153 citations
Barriers and facilitators for the sustainability of digital health interventions in low and middle-income countries: A systematic review
Soutongnoma Safiata Kaboré, Patrice Ngangue · 2022
145 citations